Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
|Articles|June 12, 2013
test
Author(s)OBGYN.net Staff
test
Advertisement
Poll Software
|
Survey Software
Answer
5. adenomyosis of the uterus
The uterus is bulky with a globular shape. Unlike a fibroid of the uterus, there is diffuse enlargement of the uterine fundus and body, without any evidence of a well-defined mass within the uterus. There is also evidence of increased vascularity and dirty shadowing typical of adenomyosis.
Advertisement
Related to this article
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
3
Reactions to FDA's boxed warning removals for menopausal hormone therapy
4
Top headlines in women's health from October 2026
5